Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Balmer

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Clinical and Vaccine Immunology : CVI|December 19, 2008
Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United KingdomJo Southern, Ray Borrow, Nick Andrews, et al.
Clinical and Diagnostic Laboratory Immunology|November 13, 2004
Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adultsJo Southern, Sarah Deane, Lindsey Ashton, et al.
BMC Public Health|December 10, 2020
Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programsMyint Tin Tin Htar, Sally Jackson, Paul Balmer, et al.
Vaccine|December 28, 2021
A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adultsDaniel Drazan, Hanna Czajka, Jason D Maguire, et al.
Clinical and Vaccine Immunology : CVI|August 9, 2006
Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?Theodore F Tsai, Ray Borrow, Hanspeter E Gnehm, et al.
Early Human Development|November 21, 2008
CSF cytokine levels in preterm infants may reflect systemic inflammation and are independent of gestationMark A Turner, Jo A Drury, Andrew Carlin, et al.
Human Vaccines|September 2, 2008
Immune response to pneumococcal conjugate vaccination in asplenic individualsElaine Stanford, Fiona Print, Michelle Falconer, et al.
Infectious Diseases and Therapy|December 4, 2023
Meningococcal Disease in the Post-COVID-19 Era: A Time to PrepareDavid E Bloom, Paolo Bonanni, Federico Martinón-Torres, et al.
Clinical and Diagnostic Laboratory Immunology|August 9, 2005
Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccineRay Borrow, Ingeborg S Aaberge, George F Santos, et al.
Vaccine|August 21, 2007
Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005Mehmet Ceyhan, Inci Yildirim, Paul Balmer, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Clinical and Vaccine Immunology : CVI|December 19, 2008
Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United KingdomJo Southern, Ray Borrow, Nick Andrews, et al.
Clinical and Diagnostic Laboratory Immunology|November 13, 2004
Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adultsJo Southern, Sarah Deane, Lindsey Ashton, et al.
BMC Public Health|December 10, 2020
Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programsMyint Tin Tin Htar, Sally Jackson, Paul Balmer, et al.
Vaccine|December 28, 2021
A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adultsDaniel Drazan, Hanna Czajka, Jason D Maguire, et al.
Clinical and Vaccine Immunology : CVI|August 9, 2006
Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?Theodore F Tsai, Ray Borrow, Hanspeter E Gnehm, et al.
Early Human Development|November 21, 2008
CSF cytokine levels in preterm infants may reflect systemic inflammation and are independent of gestationMark A Turner, Jo A Drury, Andrew Carlin, et al.
Human Vaccines|September 2, 2008
Immune response to pneumococcal conjugate vaccination in asplenic individualsElaine Stanford, Fiona Print, Michelle Falconer, et al.
Infectious Diseases and Therapy|December 4, 2023
Meningococcal Disease in the Post-COVID-19 Era: A Time to PrepareDavid E Bloom, Paolo Bonanni, Federico Martinón-Torres, et al.
Clinical and Diagnostic Laboratory Immunology|August 9, 2005
Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccineRay Borrow, Ingeborg S Aaberge, George F Santos, et al.
Vaccine|August 21, 2007
Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005Mehmet Ceyhan, Inci Yildirim, Paul Balmer, et al.
Pageof 8